ImmunityBio, Inc. (IBRX) Stock Price, Quote & News - Stock Analysis (2024)

FAQs

Is ImmunityBio a good stock to buy? ›

IBRX Stock Forecast FAQ

Currently there's no upside potential for IBRX, based on the analysts' average price target. Is IBRX a Buy, Sell or Hold? ImmunityBio has a consensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

The ImmunityBio, Inc. stock prediction for 2025 is currently $ 9.54, assuming that ImmunityBio, Inc. shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 46.79% increase in the IBRX stock price.

IBRX, +11.69% plummeted 53.7% toward a record one-day selloff in premarket trading Thursday, after the immunotherapy company disclosed it received a “complete response letter” from the U.S. Food and Drug Administration, but puts the company's Biologics License Application (BLA) for its bladder cancer treatment Anktiva ...

The US Food and Drug Administration has approved ImmunityBio's (IBRX) bladder cancer therapy, a significant milestone for the company. ImmunityBio Executive Chairman Dr.

US FDA approves ImmunityBio's bladder cancer therapy.

Largest shareholders include State Street Corp, Vanguard Group Inc, XBI - SPDR(R) S&P(R) Biotech ETF, BlackRock Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Geode Capital Management, Llc, NAESX - Vanguard Small-Cap Index Fund Investor Shares, IWM - iShares Russell 2000 ETF, VEXMX - Vanguard ...

ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio (IBRX) does not pay a dividend. Does ImmunityBio have sufficient earnings to cover their dividend? ImmunityBio (IBRX) does not pay a dividend.

But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

What is the Envx forecast for 2025? ›

Enovix Corporation Stock Prediction 2025

The Enovix Corporation stock prediction for 2025 is currently $ 12.47, assuming that Enovix Corporation shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 3.94% increase in the ENVX stock price.

Inpixon stock prediction for 1 year from now: $ 5.43 (10,209.72%) Inpixon stock forecast for 2025: $ 227.85 (432,245.13%) Inpixon stock prediction for 2030: $ 344,186,676.01T (6.53E+23%)

BioCryst to discontinue development of drug

Shares of BioCryst Pharmaceuticals Inc. were down about 5% in premarket trading on Thursday after the company said it halted development of BCX9930, which was being tested as a treatment for paroxysmal nocturnal hemoglobi...

Biolase (NASDAQ:BIOL) stock is taking a beating on Friday following the release of its earnings report for the first quarter of 2023. The bad news for investors in BIOL stock is the company's earnings per share of -18 cents for the period. That's worse than Wall Street's estimate of -10 cents for the quarter.

BCRX Stock 12 Month Forecast

Based on 7 Wall Street analysts offering 12 month price targets for BioCryst in the last 3 months. The average price target is $16.00 with a high forecast of $30.00 and a low forecast of $6.00. The average price target represents a 160.16% change from the last price of $6.15.